SACTION01:SBRT序贯替雷利珠单抗联合化疗新辅助治疗可切除非小细胞肺癌的2期试验
SACTION01为单臂、单中心2期试验,纳入46例可切除IIA-IIIB期NSCLC患者,接受原发灶SBRT(24 Gy分3次)后序贯两周期替雷利珠单抗200 mg联合铂类化疗,主要终点MPR达76%(95% CI 61-87),3级及以上治疗相关不良事件发生率为26%,耐受性可。
要点
- SBRT序贯免疫化疗新辅助治疗可切除NSCLC的MPR率为76%。
- 3级及以上治疗相关不良事件发生率为26%,最常见为中性粒细胞减少。
- 4例(9%)患者因不良事件未完成第二周期免疫化疗。
核心结论
- 术前SBRT序贯免疫化疗耐受性好、可行,并带来临床显著的MPR率。
- 未来需随机试验进一步验证该方案。
研究设计与样本
- 单臂、开放标签、单中心2期试验,纳入46例18岁及以上可切除IIA-IIIB期NSCLC患者。
- 干预为原发灶SBRT(24 Gy分3次)后序贯两周期替雷利珠单抗200 mg静脉联合铂类化疗,新辅助治疗后4-6周手术。
- 主要终点为MPR(切除肿瘤中残留活肿瘤≤10%),按意向治疗分析。
主要发现
- 46例患者中35例(76%,95% CI 61-87)达到MPR。
- 4例(9%)因肺炎(n=2)、结肠炎(n=1)、肌酐升高(n=1)未进行第二周期免疫化疗。
- 12例(26%,95% CI 14-41)发生3级及以上新辅助治疗相关不良事件。
- 最常见治疗相关不良事件为脱发(16例[35%]),最常见3级及以上为中性粒细胞减少(6例[13%])。
- 发生1例治疗相关死亡(中性粒细胞减少所致),术后90天内无死亡报告。
关键数值与推荐
- MPR定义为切除肿瘤中残留活肿瘤≤10%。
- SBRT剂量为24 Gy分3次。
- 替雷利珠单抗剂量为200 mg静脉,每周期两周期。
临床怎么用
- 该方案可作为可切除IIA-IIIB期NSCLC新辅助治疗的候选策略,需关注肺炎、结肠炎、中性粒细胞减少等不良事件。
局限性
- 单臂、单中心设计,样本量46例,缺乏随机对照。
- 试验仍在进行但已停止招募。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant immunotherapy with chemotherapy improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Given its immunomodulating effect, we investigated whether stereotactic body radiotherapy (SBRT) enhances the effect of immunochemotherapy. METHODS: The SACTION01 study was a single-arm, open-label, phase 2 trial that recruited patients who were 18 years or older and had resectable stage IIA-IIIB NSCLC from the Sun Yat-sen University Cancer Center, Guangzhou, China. Eligible patients received SBRT (24 Gy in three fractions) to the primary tumour followed by two cycles of 200 mg intravenous PD-1 inhibitor, tislelizumab, plus platinum-based chemotherapy. Surgical resection was performed 4-6 weeks after neoadjuvant treatment. The primary endpoint was major pathological response (MPR), defined as no more than 10% residual viable tumour in the resected tumour. All analyses were conducted on an intention-to-treat basis, including all patients who were scheduled for neoadjuvant treatment. The trial was registered with ClinicalTrials.gov (NCT05319574) and is ongoing but closed to recruitment. FINDINGS: Between May 18, 2022, and June 20, 2023, 46 patients (42 men and four women) were enrolled and scheduled for neoadjuvant treatment. MPR was observed in 35 (76%, 95% CI 61-87) of 46 patients. The second cycle of immunochemotherapy was withheld in four (9%) patients due to pneumonia (n=2), colitis (n=1), and increased creatinine (n=1). Grade 3 or worse adverse events related to neoadjuvant treatment occurred in 12 (26%, 95% CI 14-41) patients. The most frequent treatment-related adverse event (TRAE) was alopecia (16 [35%] patients), and the most frequent grade 3 or worse TRAE was neutropenia (six [13%]). There was one treatment-related death, caused by neutropenia. No deaths within 90 days of surgery were reported. INTERPRETATION: Preoperative SBRT followed by immunochemotherapy is well tolerated, feasible, and leads to a clinically significant MPR rate. Future randomised trials are warranted to support these findings. FUNDING: BeiGene.
引用
- Zhao ZR, Liu SL, Zhou T, et al. Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial. Lancet Respir Med. 2024. PMID: 39305910. doi:10.1016/S2213-2600(24)00215-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。